Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Change in Accured Expenses (2022 - 2025)

Axsome Therapeutics' Change in Accured Expenses history spans 4 years, with the latest figure at $7.2 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 72.05% year-over-year to $7.2 million; the TTM value through Dec 2025 reached $83.7 million, up 49.37%, while the annual FY2025 figure was $83.7 million, 49.37% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $7.2 million at Axsome Therapeutics, down from $54.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $54.2 million in Q3 2025 and bottomed at -$8.4 million in Q1 2024.
  • The 4-year median for Change in Accured Expenses is $9.3 million (2023), against an average of $13.8 million.
  • The largest annual shift saw Change in Accured Expenses crashed 217.81% in 2024 before it soared 919.11% in 2025.
  • A 4-year view of Change in Accured Expenses shows it stood at $13.2 million in 2022, then fell by 13.91% to $11.4 million in 2023, then surged by 125.95% to $25.7 million in 2024, then tumbled by 72.05% to $7.2 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Change in Accured Expenses are $7.2 million (Q4 2025), $54.2 million (Q3 2025), and $21.5 million (Q2 2025).